Updated Results of BRL-201 in R/R B-NHL; MeiraGTx and CERo Present Innovative Cell Therapy Technologies; ASGCT Spotlight on Immuno-Oncology 2023 Analysis
ASGCT Spotlight on Immuno-Oncology 2023 Analysis: BRL Medicine reported clinical updates from BRL-201’s (CD19 Quikin CAR-T) Ph1 trial in r/r B-NHL patients, while MeiraGTx and CERo Tx introduced their innovative technologies.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.